華盛鋰電(688353.SH):公司的固態電解質的相關研發仍處於實驗室研究階段
格隆匯9月10日丨華盛鋰電(688353.SH)在互動平台表示,子公司盛美鋰電因雙氟代磺酰亞胺鋰產品市場變化,停止了“第一期建設年產500噸雙氟磺酰亞胺鋰項目”試生產及項目安全設施驗收,並在原有項目設施基礎上進行生產工藝升級改造,新項目“浙江盛美鋰電材料有限公司年產3,000噸雙氟代磺酰亞胺鋰項目”已於2024年6月4日經浙江武義縣發展和改革局變更備案,公司將積極加快該項目的建設。公司按照計劃正常推進“年產20萬噸低能耗高性能鋰電池負極材料項目”一期五萬噸,爭取早日完工儘快釋放產能,助力公司業績更上一層樓。公司積極拓展研發方向,佈局未來鋰電新材料,公司的固態電解質的相關研發仍處於實驗室研究階段,尚不具備規模化、工業化的生產能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.